Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status

Expert Opinion on Drug Safety

Volumn 9, Issue 1, 2010, Pages 23-37

  Stocco, Gabriele ^a,b   Crews, Kristine R ^a   Evans, William E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Acute lymphoblastic leukemia; Inosine triphosphate pyrophosphatase; Mercaptopurine; Pharmacogenomics; Thiopurine S methyl transferase

Indexed keywords

ANTILEUKEMIC AGENT; AZATHIOPRINE; CYTARABINE; ETOPOSIDE; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; MERCAPTOPURINE; METHOTREXATE; NUCLEOTIDE TRANSPORTER; TENIPOSIDE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; ENTERITIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; HYPERBILIRUBINEMIA; INDIVIDUALIZATION; LEUKOPENIA; METASTASIS; NEUTROPHIL COUNT; NONHUMAN; PHARMACOGENOMICS; PROTEIN FUNCTION; PURINE METABOLISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXICITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; HUMANS; INDIVIDUALIZED MEDICINE; METHYLTRANSFERASES; MODELS, BIOLOGICAL; NEUTROPENIA; NUCLEOTIDE TRANSPORT PROTEINS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYROPHOSPHATASES;

EID: 74349121724     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903426151     Document Type: Review

References (91)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354(2):166-178
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371(9617):1030-1043
3. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360(26):2730-2741.
4. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007;109(10):4151-4157.
5. Rivera GK, Evans WE, Kalwinsky DK, et al. Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. J Clin Oncol 1985;3(2):201-206
6. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338(8):499-505.
7. Cheok MH, Pottier N, Kager L, Evans WE. Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol 2009 46(1):39-51
8. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429(6990):464-468.
9. Kager L, Evans WE. Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol 2006;13(4):260-265
10. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14(4):567-572
11. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348(6):538-549
12. Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: Getting personal. Am J Hum Genet 1998;63(1):11-16
13. Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 2003;63(1):100-106
14. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91(23):2001-2008.
15. Barabino A, Torrente F, Ventura A, et al. Azathioprine in paediatric inflammatory bowel disease: An Italian multicentre survey. Aliment Pharmacol Ther 2002;16(6):1125-1130 (Pubitemid 34680755)
16. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: Impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12(6):429-436
17. Stocco G, Martelossi S, Barabino A, et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 2007;13(1):57-64
18. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: Clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007;46(3):187-208
19. Elion GB. The purine path to chemotherapy. Science 1989;244(4900):41-47.
20. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003;22(47):7403-7413.
21. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126(8):608-614
22. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol 1995;47(6):1141-1147
23. Somerville L, Krynetski EY, Krynetskaia NF, et al. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 2003;278(2):1005-1011
24. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58(4):694-702
25. Hartford C, Vasquez E, Schwab M, et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 2007;67(10):4965-4972
26. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004;104(9):2690-2696
27. Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009;85(2):164-172.
28. Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006;107(2):843-844
29. Fakhoury M, Andreu-Gallien J, Mahr A, et al. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? J Clin Pharm Ther 2007;32(6):633-639
30. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105(3):696-700
31. Dokmanovic L, Urosevic J, Janic D, et al. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia. Ther Drug Monit 2006;28(6):800-806
32. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005;293(12):1485-1489
33. Relling MV, Hancock ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999;93(9):2817-2823
34. Schmiegelow K, Forestier E, Kristinsson J, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Leukemia 2009;23(3):557-564
35. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;354(9172):34-39
36. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998;12(3):346-352
37. Schmiegelow K, Al-Modhwahi I, Andersen MK, et al. Methotrexate/ 6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Blood 2009;113(24):6077-6084
38. Stanulla M, Schaeffeler E, Moricke A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols. Blood 2009;114(7):1314-1318
39. Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009;301(4):393-403.
40. Klein TE, Chang JT, Cho MK, et al. Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenetics research network and knowledge base. Pharmacogenomics J 2001;1(3):167-170
41. Krishnamurthy P, Schwab M, Takenaka K, et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 2008;68(13):4983-4989
42. Sampath J, Adachi M, Hatse S, et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci 2002;4(3):E14
43. Ansari M, Sauty G, Labuda M, et al. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 2009;114(7):1383-1386
44. Zaza G, Cheok M, Yang W, et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 2005;106(5):1778-1785
45. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;28(8):973-983
46. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004;14(3):181-187.
47. von Ahsen N, Armstrong VW, Behrens C, et al. Association of inosine triphosphatase 94C> A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem 2005;51(12):2282-2288
48. Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006;4(1):44-49
49. Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C> A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004;14(11):779-781
50. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006;55(10):1423-1431 (Pubitemid 44476786)
51. Van Dieren JM, Hansen BE, Kuipers EJ, et al. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2007;26(5):643-652
52. van Dieren JM, van Vuuren AJ, Kusters JG, et al. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 2005;54(11):1664
53. Marsh S, Van Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther 2009;85(2):139-141
54. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007;8(9):1221-1228
55. Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111(4-5):360-367
56. Behmanesh M, Sakumi K, Abolhassani N, et al. ITPase-deficient mice show growth retardation and die before weaning. Cell Death Differ 2009;16(10):1315-1322
57. von Ahsen N, Oellerich M, Armstrong VW. Characterization of the inosine triphosphatase (ITPA) gene: Haplotype structure, haplotype-phenotype correlation and promoter function. Ther Drug Monit 2008;30(1):16-22
58. Maeda T, Sumi S, Ueta A, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab 2005;85(4):271-279
59. Stenmark P, Kursula P, Flodin S, et al. Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T. J Biol Chem 2007;282(5):3182-3187
60. Stepchenkova EI, Tarakhovskaya ER, Spitler K, et al. Functional Study of the P32T ITPA variant associated with drug sensitivity in humans. J Mol Biol 2009;392(3):602-613
61. Vanderheiden BS. Genetic studies of human erythrocyte inosine triphosphatase. Biochem Genet 1969;3(3):289-297
62. Marsh S, King CR, Ahluwalia R, McLeod HL. Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet 2004;49(10):579-581
63. Okada Y, Nakamura K, Hiromura K, et al. Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus. Clin Pharmacol Ther 2009;85(5):527-530
64. Uchiyama K, Nakamura M, Kubota T, et al. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J Gastroenterol 2009;44(3):197-203
65. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000;18(5):1012-1019
66. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106(10):2258-2266
67. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 2007;25(21):3158-3167
68. Santolaya ME, Alvarez AM, Aviles CL, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J 2007;26(9):794-798
69. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100(3):345-351
70. Stocco G, Martelossi S, Barabino A, et al. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. Dig Liver Dis 2005;37(12):940-945
71. Dervieux T, Chu Y, Su Y, et al. HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin Chem 2002;48(1):61-68
72. Tay BS, Lilley RM, Murray AW, Atkinson MR. Inhibition of phosphoribosyl pyrophosphate amidotransferase from ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem Pharmacol 1969;18(4):936-938
73. Dervieux T, Blanco JG, Krynetski EY, et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61(15):5810-5816
74. Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998;87(1):108-111
75. Evans WE, Horner M, Chu YQ, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase- deficient child with acute lymphocytic leukemia. J Pediatr 1991;119(6):985-989
76. Neth O, Hann I, Turner MW, Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: A prospective study. Lancet 2001;358(9282):614-618
77. Hardy J, Singleton A. Genomewide association studies and human disease. N Engl J Med 2009;360(17):1759-1768
78. Davies SM, Borowitz MJ, Rosner GL, et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2008;111(6):2984-2990
79. Kamdem LK, Hamilton L, Cheng C, et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2008;18(6):507-514
80. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449(7164):851-861
81. Jones TS, Yang W, Evans WE, Relling MV. Using HapMap tools in pharmacogenomic discovery: The thiopurine methyltransferase polymorphism. Clin Pharmacol Ther 2007;81(5):729-734.
82. Choy E, Yelensky R, Bonakdar S, et al. Genetic analysis of human traits in vitro: Drug response and gene expression in lymphoblastoid cell lines. PLoS Genet 2008;4(11):e1000287
83. Hartford CM, Dolan ME. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics 2007;8(9):1159-1168
84. Huang RS, Duan S, Bleibel WK, et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 2007;104(23):9758-9763
85. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007;81(3):427-437
86. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358(10):999-1008
87. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302(13):1429-1436
88. Dervieux T, Bala MV. Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics 2006;7(8):1175-1184
89. Gurwitz D, Rodriguez-Antona C, Payne K, et al. Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet 2009;17(8):991-998
90. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000;2(3):E29
91. Gurwitz D, McLeod HL. Genome-wide association studies: Powerful tools for improving drug safety and efficacy. Pharmacogenomics 2009;10(2):157-159